RCUS
Arcus Biosciences, Inc.
$28.07
-0.85 (-2.94%)
At close · Jul 13
Market Cap
$3.53B
Shares
125,773,162
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.07
Open$28.24
Day$27.21–28.58
52W$8.84–31.74
Avg vol 30d1.5M
Short int12.6M · 10.1% float · 5.9d
Short vol74%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Jul 25, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+8%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
+29%
trailing
YTD return
+18%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
8 of 210 funds reported for Jun 30 · net +47.3K sh shares · +2 new
Insider flow
Distributing
Net -$265.0K over 90 days · 100% sells
Short interest
Falling
10.05% of float · ▼ -4.7% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
210 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
−5%
Y/Y
Free cash flow
$-484.0M
Balance sheet
$123.0M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+8%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $26 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
8 of 210 funds reported for Jun 30 · net +47.3K sh shares · +2 new
Insider flow
Distributing
Net -$265.0K over 90 days · 100% sells
Short interest
Falling
10.05% of float · ▼ -4.7% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
210 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $28 · 84%
52-wk high $32
vs 200-day avg +26%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCUS
this stock
Arcus Biosciences, Inc.
|
$3.53B | +17.8% | -4.3% | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$439.30B | +0.0% | +22179.2% | 894.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.89B | +5.9% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.52B | -14.0% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.76B | +4.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCUS | -6.4% | +20.5% | +28.8% | -9.0% | +17.8% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | -6.1% | +18.9% | +20.5% | -9.3% | +7.9% |